These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 29044459)

  • 21. Glycemic dysregulation in a patient with type 2 diabetes treated with 5-azacitidine: a case report.
    Ponard A; Ferreira-Maldent N; Ertault M; Delain M; Amraoui K; Regina S; Jonville-Béra AP; Hérault O; Colombat P; Gyan E
    J Med Case Rep; 2018 Jul; 12(1):199. PubMed ID: 29966534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia.
    Scott LJ
    Drugs; 2016 May; 76(8):889-900. PubMed ID: 27193945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Myelodysplastic syndrome with rapid disease progression after withdrawal of treatment with azacitidine].
    Ueda H; Yoshida M; Kanashima H; Nakao T; Sugiyama H; Yamane T
    Gan To Kagaku Ryoho; 2014 Jul; 41(7):875-7. PubMed ID: 25131875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [5-day decitabine for treatment of myelodysplastic syndromes with complex karyotype abnormalities and acute myeloid leukemia].
    Gao S; Hu XH; Qiu HY; Xu Y; Jin ZM; He GS; Tang XW; Han Y; Chen SN; Sun AN; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):542-3. PubMed ID: 23827117
    [No Abstract]   [Full Text] [Related]  

  • 25. Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study).
    Wehmeyer J; Zaiss M; Losem C; Schmitz S; Niemeier B; Harde J; Hannig CV; Harich HD; Müller J; Klausmann M; Tessen HW; Potthoff K
    Eur J Haematol; 2018 Dec; 101(6):766-773. PubMed ID: 30091166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting.
    Niscola P; Tendas A; Cupelli L; Giovannini M; Piccioni D; Scaramucci L; Dentamaro T; Del Poeta G; de Fabritiis P
    Acta Haematol; 2015; 133(1):64-6. PubMed ID: 25139255
    [No Abstract]   [Full Text] [Related]  

  • 27. NICE guidance on azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia, and acute myeloid leukaemia.
    Miller W; Holden J; George E; Stein K
    Lancet Oncol; 2011 Apr; 12(4):326-7. PubMed ID: 21598446
    [No Abstract]   [Full Text] [Related]  

  • 28. Neutrophilic panniculitis following azacitidine treatment for myelodysplastic syndromes.
    Kim IH; Youn JH; Shin SH; Yahng SA; Lee SE; Kwon JC; Lee DG; Park KS; Choi MH; Jung SE; Kim YJ
    Leuk Res; 2012 Jul; 36(7):e146-8. PubMed ID: 22483068
    [No Abstract]   [Full Text] [Related]  

  • 29. Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia.
    Falantes JF; Trujillo P; Piruat JI; Calderón C; Márquez-Malaver FJ; Martín-Antonio B; Millán A; Gómez M; González J; Martino ML; Montero I; Parody R; Espigado I; Urbano-Ispizua A; Pérez-Simón JA
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):236-44. PubMed ID: 25487600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Severe phototoxic reaction secondary to subcutaneous 5-azacitidine.
    Keating M; Dasanu CA
    J Oncol Pharm Pract; 2017 Sep; 23(6):473-475. PubMed ID: 27450683
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transient and fully reversible leukocytosis in a myelodysplastic syndrome patient upon initiation of azacitidine treatment.
    Feldmann G; Brossart P; von Lilienfeld-Toal M
    Ann Hematol; 2013 Nov; 92(11):1577-9. PubMed ID: 23584506
    [No Abstract]   [Full Text] [Related]  

  • 32. A Case of Myelodysplastic Syndrome with Intestinal Behçet's Disease-Like Symptoms Treated by Prednisolone and Azacitidine.
    Endo M; Sekikawa A; Tsumura T; Maruo T; Osaki Y
    Am J Case Rep; 2015 Nov; 16():827-31. PubMed ID: 26590106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A case of polycyclic Sweet's syndrome arising from azacitidine injection sites in myelodysplasia.
    Berry WA; Kelly R
    Ann Hematol; 2020 Jan; 99(1):201-202. PubMed ID: 31820051
    [No Abstract]   [Full Text] [Related]  

  • 34. Azacitidine-induced interstitial and alveolar fibrosis in a patient with myelodysplastic syndrome.
    Adams CD; Szumita PM; Baroletti SA; Lilly CM
    Pharmacotherapy; 2005 May; 25(5):765-8. PubMed ID: 15899739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Azacitidine-Induced Pericarditis: A Case Series.
    Newman M; Malla M; Gojo I
    Pharmacotherapy; 2016 Apr; 36(4):443-8. PubMed ID: 26940554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis.
    Falantes JF; Calderón C; Márquez-Malaver FJ; Aguilar-Guisado M; Martín-Peña A; Martino ML; Montero I; González J; Parody R; Pérez-Simón JA; Espigado I
    Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):80-6. PubMed ID: 24220615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Azacitidine and the beginnings of therapeutic epigenetic modulation.
    O'Dwyer K; Maslak P
    Expert Opin Pharmacother; 2008 Aug; 9(11):1981-6. PubMed ID: 18627335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Azacitidine-induced acute lung injury in a patient with therapy-related myelodysplastic syndrome.
    Makita S; Munakata W; Watabe D; Maeshima AM; Taniguchi H; Toyoda K; Yamauchi N; Fukuhara S; Maruyama D; Kobayashi Y; Tobinai K
    J Int Med Res; 2017 Apr; 45(2):886-893. PubMed ID: 28415946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strongly suspicious hemolysis caused by azacitidine in a myelodysplastic syndrome patient.
    Ichikawa K; Aritaka N; Ogura K; Komatsu N; Hirano T
    Geriatr Gerontol Int; 2014 Oct; 14(4):1006-7. PubMed ID: 25327907
    [No Abstract]   [Full Text] [Related]  

  • 40. Bullous variant of Sweet's syndrome.
    Voelter-Mahlknecht S; Bauer J; Metzler G; Fierlbeck G; Rassner G
    Int J Dermatol; 2005 Nov; 44(11):946-7. PubMed ID: 16336530
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.